What Fluoroquinolones Have the Highest Risk of Aortic Aneurysm? A Case/Non-case Study in VigiBase®

doi:10.1007/s11606-018-4774-2

. 2019 Apr;34(4):502-503.

doi: 10.1007/s11606-018-4774-2.

What Fluoroquinolones Have the Highest Risk of Aortic Aneurysm? A Case/Non-case Study in VigiBase®

Agnès Sommet¹, Justine Bénévent¹, Vanessa Rousseau¹, Leila Chebane¹, Antonios Douros^{2

3

4}, Jean-Louis Montastruc¹, François Montastruc^{5

6}

Affiliations

¹ Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology, INSERM UMR 1027, CIC 1426, Toulouse University Hospital, Faculty of Medicine, University of Toulouse, Toulouse, France.
² Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montréal, Québec, Canada.
³ Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montréal, Québec, Canada.
⁴ Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Clinical Pharmacology and Toxicology, Berlin, Germany.
⁵ Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology, INSERM UMR 1027, CIC 1426, Toulouse University Hospital, Faculty of Medicine, University of Toulouse, Toulouse, France. francois.montastruc@mail.mcgill.ca.
⁶ Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montréal, Québec, Canada. francois.montastruc@mail.mcgill.ca.

PMID: 30565153
PMCID: PMC6445900
DOI: 10.1007/s11606-018-4774-2

What Fluoroquinolones Have the Highest Risk of Aortic Aneurysm? A Case/Non-case Study in VigiBase®

Agnès Sommet et al. J Gen Intern Med. 2019 Apr.

. 2019 Apr;34(4):502-503.

doi: 10.1007/s11606-018-4774-2.

Authors

Agnès Sommet¹, Justine Bénévent¹, Vanessa Rousseau¹, Leila Chebane¹, Antonios Douros^{2

3

4}, Jean-Louis Montastruc¹, François Montastruc^{5

6}

Affiliations

¹ Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology, INSERM UMR 1027, CIC 1426, Toulouse University Hospital, Faculty of Medicine, University of Toulouse, Toulouse, France.
² Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montréal, Québec, Canada.
³ Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montréal, Québec, Canada.
⁴ Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Clinical Pharmacology and Toxicology, Berlin, Germany.
⁵ Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology, INSERM UMR 1027, CIC 1426, Toulouse University Hospital, Faculty of Medicine, University of Toulouse, Toulouse, France. francois.montastruc@mail.mcgill.ca.
⁶ Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montréal, Québec, Canada. francois.montastruc@mail.mcgill.ca.

PMID: 30565153
PMCID: PMC6445900
DOI: 10.1007/s11606-018-4774-2

No abstract available

Keywords: aortic aneurysms; aortic dissection; fluoroquinolones; levofloxacin.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they do not have a conflict of interest.

Cited by

Pharmacovigilance Strategies to Address Resistance to Antibiotics and Inappropriate Use-A Narrative Review.
Sandes V, Figueras A, Lima EC. Sandes V, et al. Antibiotics (Basel). 2024 May 16;13(5):457. doi: 10.3390/antibiotics13050457. Antibiotics (Basel). 2024. PMID: 38786184 Free PMC article. Review.
Effect of FluoRoquinolones on Aortic Growth, aortic stIffness and wave refLEctionS (FRAGILES study).
Gardikioti V, Georgakopoulos C, Solomou E, Lazarou E, Fasoulakis K, Terentes-Printzios D, Tsioufis K, Iliopoulos D, Vlachopoulos C. Gardikioti V, et al. Life (Basel). 2024 Aug 9;14(8):992. doi: 10.3390/life14080992. Life (Basel). 2024. PMID: 39202735 Free PMC article.
Investigating long-term risk of aortic aneurysm and dissection from fluoroquinolones and the key contributing factors using machine learning methods.
Wang HW, Huang YC, Fang YW, Jang TN, Chen M, Tsai MH. Wang HW, et al. Sci Rep. 2025 Apr 16;15(1):13130. doi: 10.1038/s41598-025-97787-6. Sci Rep. 2025. PMID: 40240493 Free PMC article.
The association between fluoroquinolones and aortic dissection and aortic aneurysms: a systematic review and meta-analysis.
Wee I, Chin B, Syn N, Lee KS, Ng JJ, Choong AMTL. Wee I, et al. Sci Rep. 2021 May 26;11(1):11073. doi: 10.1038/s41598-021-90692-8. Sci Rep. 2021. PMID: 34040146 Free PMC article.
The Research Status, Potential Hazards and Toxicological Mechanisms of Fluoroquinolone Antibiotics in the Environment.
Du J, Liu Q, Pan Y, Xu S, Li H, Tang J. Du J, et al. Antibiotics (Basel). 2023 Jun 15;12(6):1058. doi: 10.3390/antibiotics12061058. Antibiotics (Basel). 2023. PMID: 37370377 Free PMC article. Review.

See all "Cited by" articles

References

1. Daneman N, Lu H, Redelmeier DA. Fluoroquinolones and collagen associated severe adverse events: a longitudinal cohort study. BMJ Open 2015 18;5(11):e010077. - PMC - PubMed
1. Lee CC, Lee MT, Chen YS, Lee SH, Chen YS, Chen SC, Chang SC. Risk of Aortic Dissection and Aortic Aneurysm in Patients Taking Oral Fluoroquinolone. JAMA Intern Med. 2015;175:1839–47. doi: 10.1001/jamainternmed.2015.5389. - DOI - PubMed
1. Pasternak B, Inghammar M, Svanström H. Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study. BMJ. 2018;360:k678. doi: 10.1136/bmj.k678. - DOI - PMC - PubMed
1. Montastruc JL, Sommet A, Bagheri H, Lapeyre-Mestre M. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol. 2011;72(6):905–8. doi: 10.1111/j.1365-2125.2011.04037.x. - DOI - PMC - PubMed
1. Pierfitte C, Bégaud B, Lagnaoui R. Moore ND. Is reporting rate a good predictor of risks associated with drugs? Br J Clin Pharmacol. 1999;47:329–31. doi: 10.1046/j.1365-2125.1999.00881.x. - DOI - PMC - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

[1] Daneman N, Lu H, Redelmeier DA. Fluoroquinolones and collagen associated severe adverse events: a longitudinal cohort study. BMJ Open 2015 18;5(11):e010077. - PMC - PubMed

[2] Daneman N, Lu H, Redelmeier DA. Fluoroquinolones and collagen associated severe adverse events: a longitudinal cohort study. BMJ Open 2015 18;5(11):e010077. - PMC - PubMed

[3] Lee CC, Lee MT, Chen YS, Lee SH, Chen YS, Chen SC, Chang SC. Risk of Aortic Dissection and Aortic Aneurysm in Patients Taking Oral Fluoroquinolone. JAMA Intern Med. 2015;175:1839–47. doi: 10.1001/jamainternmed.2015.5389. - DOI - PubMed

[4] Lee CC, Lee MT, Chen YS, Lee SH, Chen YS, Chen SC, Chang SC. Risk of Aortic Dissection and Aortic Aneurysm in Patients Taking Oral Fluoroquinolone. JAMA Intern Med. 2015;175:1839–47. doi: 10.1001/jamainternmed.2015.5389. - DOI - PubMed

[5] Pasternak B, Inghammar M, Svanström H. Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study. BMJ. 2018;360:k678. doi: 10.1136/bmj.k678. - DOI - PMC - PubMed

[6] Pasternak B, Inghammar M, Svanström H. Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study. BMJ. 2018;360:k678. doi: 10.1136/bmj.k678. - DOI - PMC - PubMed

[7] Montastruc JL, Sommet A, Bagheri H, Lapeyre-Mestre M. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol. 2011;72(6):905–8. doi: 10.1111/j.1365-2125.2011.04037.x. - DOI - PMC - PubMed

[8] Montastruc JL, Sommet A, Bagheri H, Lapeyre-Mestre M. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol. 2011;72(6):905–8. doi: 10.1111/j.1365-2125.2011.04037.x. - DOI - PMC - PubMed

[9] Pierfitte C, Bégaud B, Lagnaoui R. Moore ND. Is reporting rate a good predictor of risks associated with drugs? Br J Clin Pharmacol. 1999;47:329–31. doi: 10.1046/j.1365-2125.1999.00881.x. - DOI - PMC - PubMed

[10] Pierfitte C, Bégaud B, Lagnaoui R. Moore ND. Is reporting rate a good predictor of risks associated with drugs? Br J Clin Pharmacol. 1999;47:329–31. doi: 10.1046/j.1365-2125.1999.00881.x. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

What Fluoroquinolones Have the Highest Risk of Aortic Aneurysm? A Case/Non-case Study in VigiBase®

Affiliations

What Fluoroquinolones Have the Highest Risk of Aortic Aneurysm? A Case/Non-case Study in VigiBase®

Authors

Affiliations

Conflict of interest statement

Similar articles

Cited by

References

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical